Alvotech has pointed to a distinct lack of other rivals in the market for golimumab biosimilars, as the firm delivered positive topline results for its AVT05 candidate.
The confirmatory clinical study for the proposed biosimilar to Janssen’s Simponi and Simponi Aria “met its primary endpoint in patients...






